Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SAF Stops Use of Usual Anti-Malaria Drug (Singapore)

This article was originally published in PharmAsia News

Executive Summary

The death of a Singapore solider due to an allergic reaction to the anti-malaria drug Maloprim has caused that country's army to cease handing it out as its typical medication. Maloprim is no longer given to Singapore solders before training in regions laden with mosquitoes in Singapore or overseas. Since April 2006, two different drugs have been handed out instead. The soldier who died from the maloprim reaction--Muhammad Sufian Jamil--experienced blood poisoning and multiple-organ failure after taking numerous doses of Maloprim between December 2005 and January 2006. Since 1985, 20,000 to 30,000 soldiers have taken maloprim annually without fatalities. Sufian, however, had an unusual condition known as Dapsone hypersensitivity syndrome, which no one knew about. The condition can cause a severe allergic reaction to an ingredient in Maloprim called Dapsone. (Click here for more - May Require Free Registration

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel